Zobrazeno 1 - 10
of 70
pro vyhledávání: '"Christopher L Parks"'
Autor:
Robert W Cross, Ira M Longini, Stephan Becker, Karin Bok, David Boucher, Miles W Carroll, Janet V Díaz, William E Dowling, Ruxandra Draghia-Akli, James T Duworko, John M Dye, Michael A Egan, Patricia Fast, Amy Finan, Courtney Finch, Thomas R Fleming, Joan Fusco, Thomas W Geisbert, Anthony Griffiths, Stephan Günther, Lisa E Hensley, Anna Honko, Ruth Hunegnaw, Jocelyn Jakubik, Julie Ledgerwood, Kerstin Luhn, Demetrius Matassov, Jeffrey Meshulam, Emily V Nelson, Christopher L Parks, Roxana Rustomjee, David Safronetz, Lauren M Schwartz, Dean Smith, Paul Smock, Ydrissa Sow, Christina F Spiropoulou, Nancy J Sullivan, Kelly L Warfield, Daniel Wolfe, Courtney Woolsey, Roland Zahn, Ana María Henao-Restrepo, César Muñoz-Fontela, Andrea Marzi
Publikováno v:
PLoS Pathogens, Vol 18, Iss 10, p e1010805 (2022)
The emergence of Marburg virus (MARV) in Guinea and Ghana triggered the assembly of the MARV vaccine "MARVAC" consortium representing leaders in the field of vaccine research and development aiming to facilitate a rapid response to this infectious di
Externí odkaz:
https://doaj.org/article/593ffe829fc54b1d9a21138ad004f3f4
Autor:
Mauricio A Martins, Young C Shin, Lucas Gonzalez-Nieto, Aline Domingues, Martin J Gutman, Helen S Maxwell, Iris Castro, Diogo M Magnani, Michael Ricciardi, Nuria Pedreño-Lopez, Varian Bailey, Dillon Betancourt, John D Altman, Matthias Pauthner, Dennis R Burton, Benjamin von Bredow, David T Evans, Maoli Yuan, Christopher L Parks, Keisuke Ejima, David B Allison, Eva Rakasz, Glen N Barber, Saverio Capuano, Jeffrey D Lifson, Ronald C Desrosiers, David I Watkins
Publikováno v:
PLoS Pathogens, Vol 13, Iss 7, p e1006529 (2017)
The ability to control lentivirus replication may be determined, in part, by the extent to which individual viral proteins are targeted by the immune system. Consequently, defining the antigens that elicit the most protective immune responses may fac
Externí odkaz:
https://doaj.org/article/7f9298477dd24bad881bb9021f08cf80
Autor:
Svetlana Rabinovich, Rebecca L R Powell, Ross W B Lindsay, Maoli Yuan, Alexei Carpov, Aaron Wilson, Mary Lopez, John W Coleman, Denise Wagner, Palka Sharma, Marina Kemelman, Kevin J Wright, John P Seabrook, Heather Arendt, Jennifer Martinez, Joanne DeStefano, Maria J Chiuchiolo, Christopher L Parks
Publikováno v:
PLoS ONE, Vol 9, Iss 9, p e106597 (2014)
Though vaccination with live-attenuated SIV provides the greatest protection from progressive disease caused by SIV challenge in rhesus macaques, attenuated HIV presents safety concerns as a vaccine; therefore, live viral vectors carrying HIV immunog
Externí odkaz:
https://doaj.org/article/36bceef9cba94e478c80cf88e3a26f5c
Autor:
Mauricio A Martins, Myrna C Bonaldo, Richard A Rudersdorf, Shari M Piaskowski, Eva G Rakasz, Kim L Weisgrau, Jessica R Furlott, Christopher M Eernisse, Marlon G Veloso de Santana, Bertha Hidalgo, Thomas C Friedrich, Maria J Chiuchiolo, Christopher L Parks, Nancy A Wilson, David B Allison, Ricardo Galler, David I Watkins
Publikováno v:
PLoS ONE, Vol 8, Iss 1, p e54434 (2013)
An effective vaccine remains the best solution to stop the spread of human immunodeficiency virus (HIV). Cellular immune responses have been repeatedly associated with control of viral replication and thus may be an important element of the immune re
Externí odkaz:
https://doaj.org/article/3908158303ba449da6ffe4b5c5342ab9
Autor:
Amy S. Espeseth, Maoli Yuan, Michael Citron, Lucia Reiserova, Gavin Morrow, Aaron Wilson, Melanie Horton, Mark Rukhman, Keith Kinek, Fuxiang Hou, Shui L. Li, Fengsheng Li, Yesle Choi, Gwen Heidecker, Bin Luo, Guoxin Wu, Lan Zhang, Erica Strable, Joanne DeStefano, Susan Secore, Tarit K. Mukhopadhyay, Douglas D. Richardson, Eddy Sayeed, Lisa S. Welch, Andrew J. Bett, Mark B. Feinberg, Swati B. Gupta, Christopher L. Cooper, Christopher L. Parks
Publikováno v:
EBioMedicine. 82
To investigate a vaccine technology with potential to protect against coronavirus disease 2019 (COVID-19) and reduce transmission of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) with a single vaccine dose, we developed a SARS-CoV-2 ca
Autor:
Christopher L. Cooper, Gavin Morrow, Maoli Yuan, John W. Coleman, Fuxiang Hou, Lucia Reiserova, Shui L. Li, Denise Wagner, Alexei Carpov, Olivia Wallace-Selman, Kristie Valentin, Yesle Choi, Aaron Wilson, Andrew Kilianski, Eddy Sayeed, Krystle N. Agans, Viktoriya Borisevich, Robert W. Cross, Thomas W. Geisbert, Mark B. Feinberg, Swati B. Gupta, Christopher L. Parks
Publikováno v:
Vaccines; Volume 10; Issue 10; Pages: 1582
Vaccines are needed to disrupt or prevent continued outbreaks of filoviruses in humans across Western and Central Africa, including outbreaks of Marburg virus (MARV). As part of a filovirus vaccine product development plan, it is important to investi
Autor:
Nuria Pedreño-Lopez, Brandon C. Rosen, Walter J. Flores, Matthew J. Gorman, Thomas B. Voigt, Michael J. Ricciardi, Kristin Crosno, Kim L. Weisgrau, Christopher L. Parks, Jeffrey D. Lifson, Galit Alter, Eva G. Rakasz, Diogo M. Magnani, Mauricio A. Martins, David I. Watkins
Publikováno v:
Frontiers in Immunology
Frontiers in Immunology, Vol 12 (2021)
Frontiers in Immunology, Vol 12 (2021)
The antiviral properties of broadly neutralizing antibodies against HIV are well-documented but no vaccine is currently able to elicit protective titers of these responses in primates. While current vaccine modalities can readily induce non-neutraliz
Autor:
Jeffrey D. Lifson, Patricia L. Earl, Bernard Moss, Dennis R. Burton, Eva G. Rakasz, Lucas Gonzalez-Nieto, Georg F. Bischof, Mauricio A. Martins, Matthias Pauthner, Nuria Pedreño-Lopez, Michael J. Ricciardi, Christine M. Dang, David I. Watkins, Christopher L. Parks, Ronald C. Desrosiers, Varian K. Bailey
Publikováno v:
J Virol
Given the complex biology of human immunodeficiency virus (HIV) and its remarkable capacity to evade host immune responses, HIV vaccine efficacy may benefit from the induction of both humoral and cellular immune responses of maximal breadth, potency,
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::cdfd0cfca14e1c2655eee56087fe99a0
https://europepmc.org/articles/PMC7925177/
https://europepmc.org/articles/PMC7925177/
Autor:
Joanne DeStefano, Aditya Arun Kumar, Aaron J. Wilson, Celia C. La Branche, Sanchari Bhattacharyya, Heather Arendt, David C. Montefiori, Mansi Purwar, Christopher L. Parks, Venkada Subramanian Vignesh, Raghavan Varadarajan, Raksha Das, Ujjwal Rathore
Publikováno v:
Journal of Biological Chemistry. 293:15002-15020
Protein minimization is an attractive approach for designing vaccines against rapidly evolving pathogens such as human immunodeficiency virus, type 1 (HIV-1), because it can help in focusing the immune response toward conserved conformational epitope
Autor:
Brian Gazzard, Makoto Inoue, Etienne Karita, Angela Lombardo, Omu Anzala, Hiroto Hara, Julien Nyombayire, Takashi Hironaka, Gloria Omosa-Manyonyi, Jill Gilmour, Patricia E. Fast, Jean Bizimana, Tsugumine Shu, Josephine H. Cox, Akil Jackson, Peter Hayes, Christopher L. Parks, Philip Bergin, Bashir Farah, Eddy Sayeed, Burc Barin, Dagna Laufer, Tetsuro Matano, Jakub Kopycinski, Len Dally, Jean-Louis Excler, Harriet Park
Publikováno v:
The Journal of Infectious Diseases
Background. We report the first-in-human safety and immunogenicity assessment of a prototype intranasally administered, replication-competent Sendai virus (SeV)–vectored, human immunodeficiency virus type 1 (HIV-1) vaccine. Methods. Sixty-five HIV-